-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cabometyx in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cabometyx in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cabometyx in Triple-Negative Breast Cancer (TNBC) Drug Details: Cabozantinib s-malate...
-
Product Insights
NewAnterior Uveitis – Drugs In Development, 2024
Empower your strategies with our Anterior Uveitis – Drugs In Development, 2024 report and make more profitable business decisions. Inflammation of the eyes is known as Uveitis. If inflammation occurs at the anterior portion of the eye (iris) it is known as anterior uveitis. Uveitis damages the uvea, the middle layer of the eye consisting of the iris, ciliary body, and choroid. Common causes are any trauma to the eye, underlying health issues like diabetes, viral infections HSV, syphilis, TB, and...
-
Product Insights
NewOcular Hypertension – Drugs In Development, 2024
Empower your strategies with our Ocular Hypertension – Drugs In Development, 2024 report and make more profitable business decisions. Ocular hypertension occurs when the pressure inside the eye (intraocular pressure) is higher than normal. If the aqueous humor does not flow through the trabecular meshwork properly, fluid pressure in the eye builds up, causing ocular hypertension. There are no symptoms with ocular hypertension. Risk factors include age, family history of glaucoma, lower systemic blood pressure, thinner central cornea, and bleeding at...
-
Product Insights
NewOpen-Angle Glaucoma – Drugs In Development, 2024
Empower your strategies with our Open-Angle Glaucoma – Drugs In Development, 2024 report and make more profitable business decisions. Open-angle glaucoma is a chronic eye condition characterized by increased intraocular pressure (IOP) that damages the optic nerve, leading to gradual and irreversible vision loss. It is the most common form of glaucoma and develops slowly over time, often without noticeable symptoms in the early stages. In open-angle glaucoma, the drainage system within the eye becomes less efficient over time, leading to...
-
Product Insights
NewUveitis – Drugs In Development, 2024
Empower your strategies with our Uveitis – Drugs In Development, 2024 report and make more profitable business decisions. Uveitis is swelling and irritation of the uvea, the middle layer of the eye. Uveitis can affect one or both eyes. Uveitis can be caused by autoimmune disorders such as rheumatoid arthritis or ankylosing spondylitis, infection, or exposure to toxins. Symptoms include blurred vision, dark floating spots in the vision, eye pain, redness of the eye, and sensitivity to light. The predisposing factors...
-
Company Insights
Enel S.p.A. – Digital Transformation Strategies
Enel Spa Digital Transformation Strategies Overview Enel S.p.A. (Enel) has been focusing on using cloud, blockchain, and cybersecurity to digitally transform its operations. The annual ICT spending of Enel was estimated at $1.8 billion for 2023. A major share of this spending is earmarked for acquiring software, network and communications, and hardware from vendors. Enel is an integrated electricity and gas company that produces, distributes, and trades electricity and natural gas. The group generates electricity using diverse sources of energy such...
-
Product Insights
NewPlaque Psoriasis (Psoriasis Vulgaris) – Drugs In Development, 2024
Empower your strategies with our Plaque Psoriasis (Psoriasis Vulgaris) – Drugs In Development, 2024 report and make more profitable business decisions. Plaque psoriasis, also known as psoriasis vulgaris, is the most common form of psoriasis, a chronic skin condition characterized by the rapid buildup of skin cells. It results from an overactive immune system, causing skin cells to accumulate on the surface, forming thick, scaly, and often itchy patches or plaques. These patches can vary in size and typically have a...
-
Product Insights
NewKeratoconjunctivitis Sicca (Dry Eye) – Drugs In Development, 2024
Empower your strategies with our Keratoconjunctivitis Sicca (Dry Eye) – Drugs In Development, 2024 report and make more profitable business decisions. Keratoconjunctivitis sicca (KCS), also called dry eye disease (DED) or dry eye syndrome (DES), is a condition in which a person experiences dryness of the conjunctiva and cornea due to an inadequate tear film. Symptoms include hyperemia, mucoid discharge, ocular irritation, photophobia, and blurry vision. Risk factors include age, wearing contact lenses, and low levels of vitamin A. Treatment includes...
-
Product Insights
NewGlaucoma – Drugs In Development, 2024
Empower your strategies with our Glaucoma – Drugs In Development, 2024 report and make more profitable business decisions. Glaucoma is a disease of the eye in which fluid pressure within the eye rises. The exact cause of optic nerve damage from glaucoma is not fully understood, but involves mechanical compression and/or decreased blood flow to the optic nerve. The most important risk factors include age, elevated eye pressure, African ancestry, thin cornea, and family history of glaucoma. Signs and symptoms include...
-
Product Insights
NewKeratoconjunctivitis – Drugs In Development, 2024
Empower your strategies with our Keratoconjunctivitis – Drugs In Development, 2024 report and make more profitable business decisions. Keratoconjunctivitis sicca (KCS), also known as dry eye syndrome (DES), dry eye disease, and keratitis sicca, is a multifactorial disease of the ocular surface caused by a loss of homeostasis of the tear film. It often results in ocular symptoms and visual disturbance due to underlying tear film instability, ocular surface inflammation and damage, and neurosensory abnormalities. The Keratoconjunctivitis drugs in development market...